SCHEMBL314919

SCHEMBL314919

Oc1cnc(Cl)c(Cl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL485560 0.97 HSD17B10 (0.42)
SCHEMBL7992204 0.75
SCHEMBL314371 0.75
SCHEMBL32671138 0.75
SCHEMBL7411078 0.75
SCHEMBL364483 0.75
SCHEMBL1765148 0.75
SCHEMBL19555715 0.75
SCHEMBL115716 0.75
SCHEMBL31483402 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US disclosed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US disclosed
EP-4634167-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE Sitryx Therapeutics Limited (GB) 2025-10-22 EP disclosed
EP-4631938-A1 NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE Shionogi & Co., Ltd (JP) 2025-10-15 EP disclosed
CN-119968366-A Oxadiazole derivatives, methods of preparation and use thereof in the treatment of inflammatory diseases 西特瑞治疗有限公司 2025-05-09 CN disclosed
EP-4543875-A1 OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES Sitryx Therapeutics Limited (GB) 2025-04-30 EP disclosed
US-12110287-B2 Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2024-10-08 US disclosed
US-20240327354-A1 GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS INSTITUT PASTEUR DE LILLE (FR) 2024-10-03 US disclosed
WO-2024127030-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LIMITED (GB) 2024-06-20 WO disclosed
WO-2024127030-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LIMITED (GB) 2024-06-20 WO disclosed
WO-1999032480-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1999-07-01 WO disclosed
US-5914328-A CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS ABBOTT LABORATORIES (US) 1999-06-22 US disclosed
WO-1998046609-A1 FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1998-10-22 WO disclosed
WO-1998025920-A1 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS ABBOTT LABORATORIES (US) 1998-06-18 WO disclosed
EP-0846114-A1 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 1998-06-10 EP disclosed
WO-1996040682-A1 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1996-12-19 WO disclosed
US-5075294-A Insecticides, miticides, nematocides HOECHST AKTIENGESELLSCHAFT (DE) 1991-12-24 US disclosed
EP-0311962-A2 Pyridil phosphates, process for their preparation, composition containing them and its use as a pesticide HOECHST AKTIENGESELLSCHAFT (DE) 1989-04-19 EP disclosed
US-4756739-A Herbicides HOECHST AKTIENGESELLSCHAFT (DE) 1988-07-12 US disclosed
EP-0227047-A2 Pyridine derivatives and their N-oxides, process for their preparation and their use as intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-01 EP disclosed